• Publications
  • Influence
Age-related macular degeneration
Age-related macular degeneration is a major cause of blindness worldwide. With ageing populations in many countries, more than 20% might have the disorder. Advanced age-related macular degeneration,Expand
  • 241
  • 28
Open Access
A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants
Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with limited therapeutic options. Here we report on a study of >12 million variants, includingExpand
  • 544
  • 27
Open Access
Systemic Complement Activation in Age-Related Macular Degeneration
Dysregulation of the alternative pathway (AP) of complement cascade has been implicated in the pathogenesis of age-related macular degeneration (AMD), the leading cause of blindness in the elderly.Expand
  • 297
  • 20
Open Access
Intravitreal aflibercept for diabetic macular edema.
PURPOSE A head-to-head comparison was performed between vascular endothelial growth factor blockade and laser for treatment of diabetic macular edema (DME). DESIGN Two similarly designed,Expand
  • 472
  • 19
Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration.
PURPOSE To test if fundus autofluorescence (FAF) patterns around geographic atrophy (GA) have an impact on GA progression rates over time in atrophic age-related macular degeneration (AMD). DESIGNExpand
  • 425
  • 18
Open Access
Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration.
PURPOSE To describe the development of new and enlargement of preexisting atrophy confined to areas with abnormally high levels of in vivo autofluorescence in eyes with geographic atrophy (GA)Expand
  • 438
  • 16
Fundus autofluorescence (FAF) imaging is a novel imaging method that allows topographic mapping of lipofuscin distribution in the retinal pigment epithelium cell monolayer as well as of otherExpand
  • 418
  • 15
Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
Background: Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD.Expand
  • 277
  • 15
High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration.
PURPOSE To describe morphologic variations in outer retinal layers in eyes with atrophic age-related macular degeneration (AMD) using high-resolution, spectral-domain optical coherence tomographyExpand
  • 234
  • 13
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
PURPOSE To investigate intraocular concentrations and pharmacokinetics of bevacizumab after a single intravitreal injection in humans. DESIGN Prospective, noncomparative, interventional caseExpand
  • 292
  • 13